Android app on Google Play

Sagent (SGNT) Launches Flumazenil Injection

January 2, 2013 4:03 PM EST Send to a Friend
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment